HIV medication options have changed significantly over the years, giving people with HIV several ways to manage the virus. Antiretroviral therapy (ART) uses combinations of medicines to prevent HIV from making copies of itself, helping reduce the amount of virus in the body and protect the immune system.
Today, treatment can involve a daily pill, a single-tablet regimen containing multiple medicines, several tablets, or certain long-acting injections. The appropriate option depends on factors such as previous treatment, drug resistance, other medications, medical conditions, potential side effects, convenience, and access to care.
HIV attacks CD4 cells, which are an important part of the immune system. Without treatment, the virus can continue multiplying and gradually damage immune function.
HIV medicines work by interfering with different stages of the viral life cycle. Using medicines from different drug classes makes it possible to suppress HIV at multiple points rather than relying on a single medicine.
The goal of treatment is viral suppression, meaning the amount of HIV in the blood becomes very low. Maintaining an undetectable viral load with effective treatment also prevents sexual transmission of HIV.
ART does not eliminate HIV from the body, so treatment needs to be continued according to the prescribed regimen. Consistent adherence is important because missed doses can make treatment less effective and can contribute to drug resistance.
HIV medicines are organized into drug classes based on how they interfere with HIV replication. Current U.S. treatment guidelines recognize several classes, including nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, integrase strand transfer inhibitors, protease inhibitors, CCR5 antagonists, attachment inhibitors, post-attachment inhibitors, and capsid inhibitors.
Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs) interfere with reverse transcriptase, an enzyme HIV needs to reproduce.
Examples include tenofovir, emtricitabine, lamivudine, abacavir, and zidovudine. NRTIs are commonly included as part of combination HIV treatment rather than being used alone.
Integrase strand transfer inhibitors (INSTIs) interfere with HIV integrase, another enzyme required for viral replication.
Examples include dolutegravir, bictegravir, and raltegravir. Integrase inhibitors are included in several modern treatment regimens, although the right medication depends on the individual's circumstances and treatment history.
Other classes can be important in specific situations, including treatment involving drug resistance or previous treatment failures.
These include protease inhibitors, NNRTIs, CCR5 antagonists, attachment inhibitors, post-attachment inhibitors, and capsid inhibitors. Some medicines in these categories are used less commonly for initial treatment but can have an important role in particular treatment plans.
One major development in HIV care is the availability of combination medicines. Instead of taking each active ingredient as a separate tablet, several medicines can be combined into one pill.
A single-tablet HIV regimen can simplify a treatment schedule for people who are appropriate candidates. Other people may use two or more tablets, co-packaged medicines, or another treatment format.
The number of pills alone does not determine whether a treatment is appropriate. A healthcare provider may consider drug interactions, resistance testing, other health conditions, side effects, and previous HIV medications before selecting a regimen.
For people researching HIV treatment options, it can therefore be useful to compare more than just the number of tablets. Dosing schedule, monitoring requirements, interactions, tolerability, and coverage can all affect the practical experience of treatment.
Not every HIV treatment requires a daily pill. Long-acting HIV medicines are administered by a healthcare professional at intervals that depend on the medication.
For HIV treatment, currently approved long-acting options include medicines such as cabotegravir and rilpivirine in Cabenuva, lenacapavir in Sunlenca, and ibalizumab-uiyk in Trogarzo. Their dosing schedules differ substantially.
Long-acting treatment can be useful for some people who have difficulty maintaining a daily medication routine. However, injections require regular healthcare appointments, and not every injectable option is appropriate for every person.
That distinction matters when comparing long-acting HIV treatment with daily pills. Convenience is only one part of the decision; treatment history, viral suppression, eligibility, scheduling, and other clinical factors also matter.
There is no single HIV medication that is appropriate for everyone. Treatment is individualized based on medical and practical considerations.
Healthcare providers may review:
Resistance testing can be particularly important because HIV can develop resistance to certain medicines. A treatment regimen that works well for one person may therefore not be appropriate for another person with a different treatment history.
Like other medications, HIV medicines can cause side effects. The specific effects vary according to the medicines used and the individual taking them.
Potential side effects and interactions are important considerations when comparing HIV medication options. Some HIV medicines can interact with other prescription drugs, over-the-counter products, or supplements.
This is one reason changing or stopping HIV medication without medical guidance can create problems. If side effects become difficult to manage, a healthcare provider can determine whether they are related to treatment and whether another regimen may be appropriate.
For people taking several medications, asking about HIV drug interactions before starting a new medicine can help avoid preventable problems.
The price of HIV treatment can vary substantially depending on the medication, insurance coverage, pharmacy, healthcare services, and assistance programs available to the patient.
People researching HIV medication costs may encounter several different types of expenses. These can include prescription costs, specialist visits, laboratory monitoring, injection administration, and other healthcare services.
Insurance coverage can also affect out-of-pocket costs. For people without adequate coverage, HIV medication assistance programs and other forms of financial support may be available depending on eligibility and location.
Because medication pricing and coverage can change, comparing the actual out-of-pocket cost for a specific treatment is more useful than relying on a general estimate. A healthcare provider, pharmacist, insurer, or HIV assistance program can help clarify the costs associated with a particular regimen.
Some HIV medicines are available in generic forms, while others are available primarily as branded products or combination formulations.
The distinction between generic and brand-name HIV medications can matter when considering prescription costs and insurance coverage. However, lower price should not be the only consideration when evaluating an HIV treatment regimen.
The active ingredients, dosing requirements, drug interactions, resistance considerations, and suitability for the individual still need to be considered. A pharmacist or healthcare provider can explain whether a generic or alternative formulation is appropriate.
Access to an experienced HIV healthcare provider is an important part of managing treatment. A provider can evaluate laboratory results, review medication history, discuss treatment choices, and monitor the response to therapy.
People searching for HIV treatment clinics or an HIV specialist may want to consider whether the care team provides medication management, laboratory monitoring, assistance with insurance or medication access, and support for maintaining treatment.
The practical side of treatment matters. A medication regimen that is medically appropriate but difficult to follow consistently may require a discussion about alternatives.
For some people, that could mean evaluating a single-tablet regimen. For others, it may involve a different combination of medicines or a long-acting treatment option when appropriate.
Before starting or changing treatment, it can be helpful to discuss several practical questions with a healthcare provider:
These questions can help turn a general discussion about HIV treatment choices into a more useful conversation about an individual's circumstances.
The main treatment is antiretroviral therapy (ART), which uses a combination of HIV medicines to suppress the virus. ART is recommended for everyone with HIV and should generally begin as soon as possible after diagnosis.
Many HIV treatments are taken as daily pills, but some long-acting treatments are administered by a healthcare professional at longer intervals. The appropriate schedule depends on the specific treatment and the individual's medical circumstances.
Current HIV treatment does not cure HIV. Instead, ART suppresses the virus, protects immune function, and can reduce the amount of virus to an undetectable level.
Providers consider factors such as treatment history, drug resistance, other medical conditions, possible interactions, side effects, convenience, and access to medication when selecting a regimen.
Yes. Several long-acting HIV medicines are approved in the United States for treatment. Depending on the medication, injections may be given every few weeks or months rather than requiring a daily pill.
Potential sources of assistance can include health insurance, healthcare programs, medication assistance programs, and other local or national resources. Eligibility and coverage vary, so discussing costs with a healthcare provider, pharmacist, insurer, or HIV care organization can help identify available options.